{'fraction_non_alphanumeric': 0.03496503496503497, 'fraction_numerical': 0.009324009324009324, 'mean_word_length': 5.515151515151516, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
c‐erbB‐2 oncoprotein: A potential biomarker of advanced prostate cancer

Overexpression of the c‐erbB‐2 oncogene has been implicated in the development and/or prognosis of several human carcinomas, including that of the prostate. Recently, c‐erbB‐2 protein was found to be released in the circulation. The present study was undertaken to study the significance of serum c‐erbB‐2 protein determination in men with prostate cancer.